The additional risk for adverse health outcomes · attributable to the milder degrees of maternal hyperglycemia associated with GDM and the magnitude of the benefit from treating that risk are less certain. No well-designed and conducted randomized controlled trial (RCT) of screening for 1 GDM has been completed, and thus the evidence for screening is indirect.
National groups disagree about whether to recommend screening for GDMY-11 Despite no strong recommendations in favor of universal screening from the American College of Obstetricians and Gynecologists (ACOG), 94% of Fellows in office-based practices reported performing universal screening for GDM in 1996.
12
Fellows performed this screening even though ACOG acknowledged the weakness in the evidence in both 1994 13 and 2000.'
With continued controversy around the advisability of GDM screening, the RTI-University of North Carolina Evidence-based Practice Center (RTI-UNC EPC) conducted a systematic evidence review to assist the U.
S. Preventive Services Task
Force (USPSTF) in reconsidering its 1996 review, which found insufficient evidence to recommend screening. We restricted this review to screening for GDM after 24 weeks' gestation, thus excluding both women with known pregestational diabetes and those who are discovered by symptoms earlier in pregnancy.
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I Materials and Methods
Sources
Our review of the literature was guided by key questions and inclusion criteria we developed relevant to the issue of screening for GDM (Table 1) . We required RCTs for direct evidence of the efficacy of treatment and the harms associated with treatment. We examined the critical literature from the 1996 USPSTF review and searched MEDLINE and the Cochrane Library for reviews and relevant studies published in English between January I, 1994 and August 30, 2002 . We supplemented this search by examining the reference lists of pertinent articles and by contacting experts. We also conducted focused searches ofMEDLINE from 1966 through 1994 to identify older articles of interest.
Note: AU searches started with exploding "diabetes, gestational."
Study Selection
All searches began by exploding the term "diabetes, gestational" and then proceeded by adding further terms. We retrieved the full text of all articles we thought were potentially eligible. Two reviewers examined each article for eligibility. A single reviewer abstracted relevant data from the included articles; a second reviewer checked the abstractions.
We abstracted all included articles, entered the data into evidence tables, graded the quality of all articles according to USPSTF criteria, 14 and resolved disagreements by discussion. We synthesized the evidence into a systematic evidence review; this was subjected to extensive external peer review and revised as appropriate. 15 The final systematic evidence review, including the evidence tables, is available on the Agency for Healthcare Research and Quality (AHRQ) Web site (www.preventiveservices.ahrq.gov). This article summarizes the evidence from that review.
Results
For the USPSTF to recommend screening for GDM, it must have either direct evidence from a randomized controlled rrial (RCT) of screening or indirect evidence that establishes a complete linkage between screening and improved health outcomes. We found no well-conducted RCT that provides direct evidence for the health benefits of screening for GDM. Given this, the USPSTF requires adequate evidence that: (!) untreated GDM causes substantial maternal and/or neonatal adverse health outcomes; (2) available screening tests accurately and efficiently detect GDM; and (3) available treatments improve health outcomes, with a magnitude that clearly justifies the harms and effort of screening and treatment. These issues will be examined in the sections that follow.
What Adverse Health Outcomes Occur with Untreated GDM?
Determining the existence and magnitude of a causal association between various degrees of GDM and adverse health outcomes is complex. We have only older studies of untreated GDM, at a time when obstetric practice differed from current practice, or more recent studies in which women received some treatment for GDM. Another problem with many studies is that they consider GDM as a dichotomous variable, yet we know that the risk for adverse health outcomes increases with the degree of hyperglycemia among women with GDM; the impact of hyperglycemia on adverse maternal and neonatal health outcomes is probably continuous. 
Offspring Health Outcomes
BecaUse the literature is scant and mixed about whether untreated GDM, given optimal obstetric care today, is associated with increased perinatal 3 mortality, 1 9-27 the extent to which GDM is truly associated with perinatal mortality remains unclear.
Macrosomia is an intermediate outcome of GDM. Three recent studies of untreated women with GDM"·"'"found that the percentage of infants with macrosomia weighing more than 4,000 grams was berween about 17% and 29%; the percentage in the general population is about 10%. 26 Most infants with macrosomia are born to women without GDM 28 ; maternal obesity is an important potential confounding factor associated with both GDM and (independently) with macrosomia.
Important adverse neonatal health outcomes linked to macrosomia are brachial plexus injury and clavicular fracture. The best (although minimal) data on untreated women with GDM compared with the non-GDM population reveal no difference in the rate of infant brachial plexus injury or clavicular fracture. 22 Recent data suggest that women treated for GDM with more severe degrees of hyperglycemia may have a 2% absolute increase in having their infants develop a brachial plexus injury and a 6o/o increase in having their infants develop a clavicular fracture."-'' While these adverse health outcomes are of concern, the best studies show that 80% to 90% of brachial plexus injuries resolve by one year of life, 
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GDM may also be a risk factor for neonatal hypoglycemia. Studies among untreated" and treated women with GDM have found higher rates of neonatal hypoglycemia among untreated women with GDM. The magnitude of clinically important neonatal hypoglycemia is less clear. Also not clear is whether increased surveillance of infants whose mothers have GDM contributes to the increased finding of hypoglycemia in their infants.
Likewise, the evidence is limited and unclear as to whether GDM is associated with preterm birth or neonatal hyperbilirubinemia, hypocalcemia, or polycythemia. 1 .2n.3s, 4 0-44 Because of limited evidence and the increased surveillance given to infants of women with GDM, the magnitude of any t One or more criteria must be met or exceeded for a positive diagnosis.
Note: Double dash (-) indicates glucose levels not used for the test indicated.
Screening Tests. The thresholds for the reference diagnostic tests do not dearly distinguish women at high risk from women at low risk for adverse maternal or neonatal health outcomes from GDM. Thus, we can evaluate screening tests only against imperfect standards. Most studies on GDM screening strategies compare the results of 1 test with the results of another test rather than examining how the test predicts adverse health outcomes. Some studies assess the association of the test with intermediate outcomes such as macrosomia rather than health outcomes such as brachial plexus injury.
In the United States, the 50-gram, !-hour glucose challenge test {GCT) is most commonly used for screening {Table 2). Two groups have proposed different threshold criteria to define a positive screening test. If the GCT glucose value is above either 130 mg/dL 77 or 140 mg/dL, 65 then the patient is usually given the 100-gram GTT for diagnosis. Using the 130 mg/dl threshold, the GCT is positive for 20% to 25% of all pregnant women, including 90% of women with GDM. Using the 140 mg/ dl threshold, the GCT is positive for 14% to 18% of all pregnant women, including about 80% of women with GDM."
In the general population, false-positive results for the GCT are common. Fewer than 1 in 5 women with a positive GCT will meet criteria for 5 GDM on a full 100-gram GTT." The reliability of the GCT is also problematic."
In many countries outside North America, clinicians use the "WHO screening approach: the 75-gram 2-hour oral GTT as a single-step screening and diagnostic test. As noted above, this approach identifies at least twice as many women as having GDM as the two-step approach, although the evidence is sparse about whether the one-step test is more or less predictive of adverse health outcomes thaD; the two-step approach. 68 • 69
Because glucose intolerance increases during pregnancy, screening for GDM is most commonly conducted during the 24rh to 28th week of gestation. However, this timing is not based on any evidence that this is the optimal time to identify women who would benefit most from treatment. Determining the best time to screen involves examining the trade-off between the potential benefits of early screening (ie, finding fewer women at higher risk and treating them for a longer time) and the potential benefits of later screening {ie, finding a larger number of women at lower risk and treating them for a shorter time). 19 We found no study on this issue.
One suggested approach to improve the efficiency of screening for GDM is to restrict screening to women at higher risk {"selective screening") rather than screening all women ("universal screening"). In the most detailed study of selective screening strategies, Naylor et al developed a scoring system that excluded nearly 35o/o of women from screening and actually detected more cases of G D M than universal screening.
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In summary, the evidence is unclear about the optimal screening and reference diagnostic test for screening for GDM.
Does Treatment for GDM Improve Health Outcomes?
Glycemic Control
Three-factors are important in considering studies that evaluate the impact of tight glycemic control on health outcomes for women with GDM. The first is the degree of hyperglycemia in study participants. As the risk for at least some adverse health events increases with an increasing degree of hyperglycemia, the potential absolute risk reduction may be larger wirh higher glycemic levels. More than 70o/o of women diagnosed with GDM have mild hyperglycemia and are usually treared with diet alone.
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The second important factor is the degree of separation of glycemic control between treatment groups. If intensive treatment does not produce a reasonable reduction in glycemic level compared with conventional treatment (or no treatment), the hypothesis of improved glycemic control leading to better health outcomes cannot be tested.
The third factor in considering these studies is assessment of outcomes: which ones to assess and how to assess them. Most of these studies focused on intermediate outcomes such as fetal macrosomia or chemical findings such as neonatal hypoglycemia. Intermediate outcomes are useful only insofar as they predict important health outcomes that people care about.
14 In the case of fetal macrosomia, an intermediate outcome, only a small percentage of these cases lead to maternal or neonatal trauma. In the case of chemical findings (eg, glucose or bilirubin level), few studies reported the percentage of abnormalities that required 1 treatment; no study was clearly reassuring that 6 differences attributed to improved glycemic control were not associated instead with more intense surveillance of infants born to GDM mothers. Finally, because few of these studies masked the obstetricians, 80 • 81 interventions or outcomes that depend on clinician judgment (eg, cesarean delivery rates) could be biased by knowledge of GDM status. Table 3 records clara from 9 RCTs examining rhe impact of therapy on a variety of outcomes. Three RCTs compared intensive with less intensive glycemic control (achieving some glycemic separation) among women with GDM who had varying degrees of hyperglycemia but a low mean entry fasting plasma glucose (FPG) or mean hemoglobin Ale (HbAlc)."·"·" Two studies found statistically significant improvements in intermediate outcomes for those women undergoing intensive glycemic control (eg, fewer large for gestational age [ LGA] infants"; lower incidence of neonatal hypocalcemia"); no study found clear differences in health outcomes between glycemic control groups.
Severe hyperglycemia. Four RCTs examined tight and less tight glycemic control among women with GDM at more severe hyperglycemic levels ( Table 3 )."·"·"'·" Of these trials, 3 achieved eirher small or no difference in glycemic control between groups and found no difference in major outcomes. One study achieved a larger glycemic separation between groups {difference in mean glucose, 24 mg/dL)." The infants of!ess intensively treated women had a higher mean birth weight plus higher rates of neonatal hypoglycemia and polycythemia. These differences were small and of uncertain clinical importance. A major issue in all of these trials is that they have too few participants to be able to detect small differences among treatment groups in such uncommon adverse health outcomes as perinatal mortality and brachial plexus injury. They have even less power to determine whether the health benefit is different for women with GDM who have severe hyperglycemia compared with those who have mild hyperglycemia. They provide insufficient evidence to confirm or refute the hypothesis that glycemic control improves health outcomes for women with
GDM.
Several observational studies without randomized controls have suggested improved intermediate or health outcomes with more intensive treatment of women with GDM.22.n.ss- 91 The weakness in these studie·s is that women in the treatment groups differ from women in the control groups in multiple ways (some known and some unknown) other than glycemic control; most of the known factors are also associated with health outcomes. Thus. observed improvements in health outcomes may be attributable to factors other than glycemic control.
In summary, although insulin therapy decreases the incidence of fetal macrosomia for those women with more severe degrees of hyperglycemia, the magnitude of any effect on maternal and neonatal health outcomes is not clear. The evidence is insufficient to determine the magnitude of health 7 benefit of tight glycemic control among the large number of women with GDM at milder degrees of hyperglycemia.
Antepartum Surveillance
Various approaches to antepartum surveillance might improve health outcomes among women with GDM. For non-stress testing {NST) or biophysical profile {BPP) to constitute a rationale for GDM screening, evidence would need to show that the use of these tests reduces stillbirth among women with GDM who have no other indication for these tests. This would require a large RCT, as most women with GDM have a low risk for having a stillbirth. No completed study of women with GDM has examined he:Mth outcomes among groups randomized to receive or not receive NST or BPP.
Observational studies have found that using NSTs or BPPs in women with GDM is associated with either absent or very low rates of stillbirth.
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Without appropriate control groups we do not know whether the low rate of fetal death can be attributed to the additional procedures.'' NSTs or BPPs have high false-positive rates,"'" and they lead to interventions 94 that may, on occasion. be unnecessary.
Ultrasound assessment of abdominal circumference to allow improved targeting of insulin therapy in order to decrease fetal macrosomia and birth trauma has been studied. Three RCTs have enrolled women with hyperglycemia into insulin therapy triggered by ultrasound abdominal circumference. 29 ' 83 ' 96 These studies have not found any important differences in health outcomes; all 3 lacked power to detect differences in health outcomes and in none were the obstetricians masked to the intervention group.
What are the Harms and Costs of Screening and Treatment?
Precise evidence on the harms and costs of screening for GDM and early treatment is lacking. Although not well documented, the potential for adverse psychological effects from screening is real;
in the general population, more than 80% of all positive GCT screening tests are false positives. 97 j_ Note: AC indicates abdominal circumference; CPO, cephalopelvic disproportion; GDM, gestational diabetes meHitus; NDDG, National Diabetes Data Group; NR, not reported; NS, not statistically significant; stat sig, statistical significance; WHO, World Health Organization.
continued on page 10
Note: AC indicates abdominal circumference; CPO, cephalopelvic disproportion; GDM, gestational diabetes mellitus; NDDG, National Diabetes Data Group; NR, not reported; NS, not statistically significant; stat sig, statistical significance; WHO, World Health Organization. 
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As the effectiveness of screening in imprOving health outcomes is uncertain, so the cost-effectiveness cannot be calculated with any precision. We do not have good information about the differences in health care costs between screened and unscreened women.
Discussion
Maternal and neonatal morbidity increase with increasing levels of maternal hyperglycemia. Screening and intensive treatment for GDM aim to reduce this morbidity. Various screening strategies can detect women with different degrees of hyperglycemia, but the threshold at which health outcomes begin to deteriorate to a clinically important degree is uncertain.
The magnitude of any benefit of intensive treatment at the various levels of hyperglycemia associated with GDM is also uncertain, but it is likely to be small among the many women with mild hyperglycemia. For women with GDM who have more severe hyperglycemia, intensive treatment is likely to reduce macrosomia. The extent to which · this translates into reductions in birth trauma is uncertain but probably substantially less than reductions in macrosomia.
The evidence about the health outcomes of intensive treatment of women with GDM at various 12 levels of maternal hyperglycemia is indirect. It is also limited by a small number of srudies, small number of participants, lack of masking of obstetrical care, lack of control for important confounders, and lack of emphasis on health outcomes rather than intermediate outcomes.
By making various assumptions, we can calculate
the number needed to screen (NNS) to prevent various adverse health outcomes. Take, for example, the number of women needed to screen to prevent I case of brachial plexus injury ( Table 4 ). Assume that 4% of pregnant women have GDM,' that 30% of them will have a high enough glycemic level to require insulin/ 9 and that, among these women, the macrosomia rate is reduced to the degree seen in the most positive srudy." The NNS to prevent one brachial plexus injury is about 8,900 (Case I, Table 4 ).
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103 If we make more generous assumptions, the NNS becomes 3,300 (best case scenario, shown in Case 3 and footnote, Table 4 ).
Assumptions including a lesser reduction in macrosomia, accounting for cesarean delivery rates, or using an outcome of permanent brachial plexus injury, would give much higher NNS estimates.'
One potential benefit of detecting women with GDM is the knowledge that they have a higher risk for developing type 2 diabetes. The extent to which this information can lead to a health benefit for younger women with few cardiovascular risk factors, however, is uncertain. 
